Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.46 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALB | P02768 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.41 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.39 |
| ▸ | POLA1 | P09884 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ddctp SCHEMBL30586989 | 0.91 | POLG (0.70) | POLGPOLBP2RY2P2RY4P2RY6 | |
| Ddctp SCHEMBL18840498 | 0.91 | POLG (0.70) | POLGPOLBP2RY2P2RY4P2RY6 | |
| Ddctp SCHEMBL20879464 | 0.91 | POLG (0.70) | POLGPOLBP2RY2P2RY4P2RY6 | |
| Ddctp SCHEMBL210922 | 0.91 | POLG (0.70) | POLGPOLBP2RY2P2RY4P2RY6 | |
| Ddctp SCHEMBL16807754 | 0.91 | POLG (0.70) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL543438 | 0.91 | POLG (0.67) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL23157013 | 0.87 | POLG (0.55) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL21895844 | 0.87 | POLG (0.55) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL23157216 | 0.87 | POLG (0.55) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL454264 | 0.87 | POLG (0.55) | POLGPOLBP2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180355406-A1 | POLYNUCLEIC ACID MOLECULE ENRICHMENT METHODOLOGIES | GENETICS RESEARCH, LLC, D/B/A ZS GENETICS, INC. | 2018-12-13 | — | — | US | claimed |
| EP-4580609-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2025049632-A1 | COMPOSITIONS AND METHODS FOR BROAD DELIVERY OF RNA TO TISSUE | REJUVENATION TECHNOLOGIES INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2024050372-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| EP-4271389-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| WO-2022147039-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-11142788-B2 | Isolation of target nucleic acids | GENETICS RESEARCH, LLC (US) | 2021-10-12 | — | — | US | disclosed |
| US-20180355419-A1 | ISOLATION OF TARGET NUCLEIC ACIDS | HARBINGER HEALTH, INC. | 2018-12-13 | — | — | US | disclosed |
| US-20180355406-A1 | POLYNUCLEIC ACID MOLECULE ENRICHMENT METHODOLOGIES | GENETICS RESEARCH, LLC, D/B/A ZS GENETICS, INC. | 2018-12-13 | — | — | US | disclosed |
| US-20170037465-A1 | Methods for Nucleic Acid Base Determination | TSAVACHIDOU DIMITRA (US) | 2017-02-09 | — | — | US | disclosed |
| WO-2015089511-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-8614312-B2 | Method for preparing nucleotides and related analogues by synthesis on soluble substrate, and biological tools thus prepared | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-12-24 | — | — | US | disclosed |
| US-20110118454-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-05-19 | — | — | US | disclosed |
| EP-2265624-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | Centre National de la Recherche Scientifique (FR) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009115694-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118454-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | PNP, NUDT1, DUT | POLG 585/4885POLB 209/4885P2RY2 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.